Clinical trials: SARS-COV2 Virus
Covid19
Clinical Performance Evaluation of KnowNow SARS-CoV-2 Test for the Detection of COVID-19 Antigen
This is an international, multicentre, non-interventional, observational study to assess the clinical diagnostic performance of a rapid, point of care (POC) COVID-19 (SARS-CoV-2) antigen In vitro diagnostic (IVD), The KnowNow…
- Trial name
- NCT04733170
- Testing
- KnowNow SARS-CoV-2 Rapid Antigen Test
- Volunteers
- 600 people
- Sponsor
- Vatic Ltd.
SARS-CoV
Validation of a Rapid, Non-invasive Point-of-care IVD Test for Diagnosis of SARS-COV-2 (COVID-19) Infection
A prospective non-interventional study to evaluate the performance of EASYCOV IVD as point-of-care (POC) test by comparing SARS-CoV-2 positive patients with SARS-CoV-2 negative controls on paired specimens (nasopharyngeal swabs…
- Trial name
- EasyCov (NCT04583319)
- Testing
- EasyCov POC
- Where
- Turkey (Türkiye)
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Firalis SA
SARS-CoV-2
Clinical Trial of COVID-19 Vaccine（SARS-CoV-2 Variant(Omicron BA.5) mRNA Vaccine） in Participants Aged 18 Years and Over
This is a single-center, randomized, blinded, placebo-controlled clinical trial to evaluate the protective efficacy, safety and immunogenicity of one dose of the SARS-CoV-2 variant (Omicron BA.5) mRNA vaccine in people aged 18…
- Trial name
- NCT05745545
- Testing
- SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine, Saline solution
- Where
- China
- Volunteers
- 3,200 people, healthy volunteers welcome
- Sponsor
- AIM Vaccine Co., Ltd.
COVID-19 Pandemic
Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Phase III
A Global, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) in Adults Aged 18 Years…
- Trial name
- COVID-19 (NCT05096845)
- Testing
- Recombinant SARS-CoV-2 fusion protein vaccine (V-01), Blank Preparation of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)
- Where
- 25 sites in Indonesia, Philippines and 1 more
- Volunteers
- 22,500 people, healthy volunteers welcome
- Sponsor
- Livzon Pharmaceutical Group Inc.
Vaccine Response Impaired, Vaccine Adverse Reaction
Vaccine Observation to Include All Communities for Equitable Science
VOICES is a longitudinal, prospective, observational study that will enroll up to 10,000 subjects of diverse racial backgrounds being administered an emergency use authorized COVID-19 vaccine, for collection and analysis of stool…
- Trial name
- VOICES (NCT04770649)
- Testing
- COVID-19 vaccine
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Persephone Biosciences
Acute Respiratory Distress Syndrome, SARS-CoV-2
Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19
Evaluation of the safety, tolerability, and pharmacokinetics of PLN-74809 in participants with acute respiratory distress syndrome (ARDS) associated with at least severe COVID-19
- Trial name
- NCT04565249
- Testing
- PLN-74809
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- Pliant Therapeutics, Inc.
COVID-19 Vaccines
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age
The purpose of this study is to learn about the safety and effects of an updated COVID-19 vaccine (called BNT162b2) in adults 18 to 64 years of age.
- Trial name
- NCT07730450
- Testing
- BNT162b2 Vaccine, Tdap Vaccine
- Where
- 5 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
COVID-19, Vaccines
Immunogenicity and Safety of AdCLD-CoV19-1 OMI As a Booster: a COVID-19 Preventive Vaccine in Healthy Volunteers
The immunogenicity and safety of AdCLD-CoV19-1 OMI (5.0x10^10 VP (0.5 mL)/dose/Vial) administered as a booster in healthy adults aged 19 years old and above will be evaluated.
- Trial name
- COVID-19 (NCT05993325)
- Testing
- AdCLD-CoV19-1 OMI, Comirnaty Bivalent 0.1mg/mL (tozinameran and riltozinameran)
- Where
- 17 sites in Philippines, South Korea
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- Cellid Co., Ltd.
2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection
Leidos-Enabled Adaptive Protocol for Clinical Trials (LEAP-CT) in Hospitalized Patients With COVID-19 (Addendum 1)
This study is designed to test the efficacy and safety of combinations of two well-understood agents - famotidine and celecoxib in patients hospitalized with moderate-to-severe COVID-19 (based on World Health Organization [WHO]…
- Conditions
- 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease, 2019-nCoV Infection
- Trial name
- NCT05085574
- Testing
- Famotidine, Celecoxib
- Sponsor
- Leidos Life Sciences
SARS-CoV-2 Infection, Bacterial Respiratory Tract Infection
Shifts in the Respiratory Microbiome and Clinical Outcomes of SARS-CoV-2
This is a longitudinal, prospective observational study focusing on health-related outcomes relative to potential changes in the respiratory microbiome seen with weekly SARS-CoV-2 testing in nursing home residents.
- Conditions
- SARS-CoV-2 Infection, Bacterial Respiratory Tract Infection, Viral Respiratory Tract Infection
- Trial name
- COVID-19 (NCT04815018)
- Where
- 4 sites in United States
- Volunteers
- 185 people, healthy volunteers welcome
- Sponsor
- Pathnostics
ARDS Due to COVID-19
Surfactant-BL in Adult Acute Respiratory Distress Syndrome Due to COVID-19
The purpose of this study is to prove the efficacy and safety Surfactant-BL, administered by inhalation in adult hospitalized patients with ARDS due to COVID-19.
- Trial name
- NCT04568018
- Testing
- Surfactant
- Where
- Russia
- Volunteers
- 120 people
- Sponsor
- Biosurf LLC.
SARS-CoV-2 Infection
A Phase 1/2 Study to Assess the Safety, Tolerability and Pharmacokinetics of NGM621 in Healthy Subjects, and to Assess the Safety, PK and Efficacy in Subjects With Moderate to Severe ARDS Caused by COVID-19
This study is a combined Phase 1 and Phase 2 study with IV infusion of NGM621 to evaluate the safety, tolerability, and PK in healthy volunteers (Part 1), and safety, tolerability, PK and efficacy in subjects with confirmed…
- Trial name
- NCT04582318
- Testing
- NGM621
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- NGM Biopharmaceuticals, Inc
COVID-19, Acute Respiratory Distress Syndrome (ARDS)
Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019
This was a Phase 2, randomized, double-blind, placebo-controlled, parallel-group, multicenter, dose escalation and proof-of-concept study to evaluate the safety and efficacy of razuprotafib, administered 3 times daily (TID)…
- Trial name
- RESCUE (NCT04511650)
- Testing
- Razuprotafib Subcutaneous Solution
- Where
- 7 sites in United States
- Volunteers
- 31 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
COVID-19
A Clinical Trial of Mycobacterium w in Critically Ill COVID 19 Patients
The trial is randomized, blinded, two arms, active comparator controlled, clinical trial to evaluate the safety and efficacy of Mycobacterium w in combination with standard care as per hospital practice versus standard care alone…
- Trial name
- NCT04347174
- Testing
- Suspension of heat killed (autoclaved) Mycobacterium w
- Where
- 4 sites in India
- Volunteers
- 40 people
- Sponsor
- Cadila Pharnmaceuticals
COVID-19
Preventive Dendritic Cell Vaccine, AV-COVID-19, in Subjects Not Actively Infected With COVID-19
This is a phase 2 randomized, double-blind clinical trial testing an anti-SARS-CoV-2 COVID-19 vaccine (AV-COVID-19) made on site using PT AIVITA Biomedika Indonesia's vaccine-enabling kit for the prevention of COVID-19 infection.
- Trial name
- NCT05007496
- Testing
- AV-COVID-19
- Where
- Indonesia
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- Aivita Biomedical, Inc.
COVID-19, SARS-CoV2
Anti-Androgen Treatment for COVID-19
This study is intended to explore the possible protective role of anti-androgens in SARS-CoV-2 infection
- Conditions
- COVID-19, SARS-CoV2, Androgenetic Alopecia, Prostate Cancer
- Trial name
- NCT04446429
- Testing
- Proxalutamide, Standard of Care
- Where
- Brazil
- Volunteers
- 268 people
- Sponsor
- Applied Biology, Inc.
Covid19
Performance Assessment of SARS-CoV-2 Detection Breath Biopsy - SARS-CoV-2 Study
The primary aim of this study is to investigate the performance of Breath Biopsy RD for the detection of SARS-CoV-2 in both a clinical and at home setting.
- Trial name
- COVID (NCT04508556)
- Testing
- Breath Biopsy face masks with removable filters and fitted PVA strip, Nasopharyngeal swab, oropharyngeal swabs
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Owlstone Ltd
COVID-19
Immunogenicity and Safety of Adjuvanted SCB-2020S Vaccines in Adults
This is a phase 2, randomized, controlled, observer-blind study to evaluate the immunogenicity and safety of different formulations of the investigational adjuvanted recombinant SARS-CoV-2 trimeric S-protein (from B.1.351…
- Trial name
- NCT04950751
- Testing
- candidate vaccine, SCB-2020S
- Volunteers
- healthy volunteers welcome
- Sponsor
- Clover Biopharmaceuticals AUS Pty
COVID-19
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
This is a Phase 2/3 open-label study to evaluate the safety and immunogenicity of a booster dose of the XBB.1.5 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant (r) spike (S) protein nanoparticle vaccine…
- Trial name
- COVID-19 (NCT05975060)
- Testing
- XBB.1.5 Vaccine (Booster), XBB.1.5 Vaccine (single dose)
- Where
- 30 sites in United States
- Volunteers
- 660 people
- Sponsor
- Novavax
COVID-19, SARS-CoV-2
Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults
The aim of the study is to assess the safety, efficacy, and immunogenicity of AZD1222 for the prevention of COVID-19.
- Trial name
- NCT04516746
- Testing
- AZD1222
- Where
- 84 sites in United States, Chile and 1 more
- Volunteers
- 32,450 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.